Hormone Therapy Safety: Medical Journals Request Expert Opinions From Global Leader and UCLA Professor

Share Article

A series of research conducted by age-management leader Cenegenics® Medical Institute with noted UCLA professor Dr. Ernst von Schwarz garnered the medical community’s recognition as experts on hormonal therapy

Based on our experience and research, when we've used testosterone therapy with patients having underlying cardiovascular disease (elderly men and women), we saw very good results without cardiovascular events.

Cenegenics® Medical Institute, the global age management medicine leader, collaborated with Dr. Ernst R. von Schwarz—professor of medicine at UCLA’s David Geffen School of Medicine—for a series of scientific review papers focused on aging, cardiovascular health and hormone therapy. Their collaborative work and longtime experience in the field recently garnered recognition from two medical journals, who requested follow-up expert reviews from the Cenegenics-von Schwarz research team for upcoming publication.

Hormonal therapy is a key interest of both medical journals. The first—Expert Review of Cardiovascular Therapy—commissioned Cenegenics-von Schwarz for updates on growth hormone and hormone therapy in general, as related to cardiovascular treatment. The second journal—Expert Opinion of Drug Safety—is of particular importance, given the media’s concentration on negative effects of testosterone therapy.

“A later study published in the New England Journal of Medicine found that testosterone therapy used on men having underlying cardiovascular disease produced higher-rate outcomes for events. But if you look at those events in detail, they were edema or palpitations, not hard outcomes. We have a completely different opinion, based on our experience and research. When we’ve used testosterone therapy with patients having underlying cardiovascular disease—both elderly men and women—we saw very good results without cardiovascular events, which is why the journal is requesting our expert opinion on the safety of testosterone therapy,” von Schwarz said.

That’s important, per von Schwarz, because people are confused about the safety issues. Consequently, they steer away from protocols not in the guidelines and become scared—more so in the U.S. than in any other country.

“In our opinion, it is safe to use testosterone therapy in a majority of patients as long as the therapy is controlled with follow-ups, with blood levels checked and with the baseline PSA levels checked,” von Schwarz said.

Cenegenics—via its nonprofit Cenegenics Education and Research Foundation (CERF)—plans further research and scientific expert reviews throughout 2011. The global giant stands committed to identify institutions, researchers and research organizations who are interested in investigating markers for aging and solutions to slow down the progression of chronic disease via a proactive approach.

With cardiovascular disease topping the list as a major killer in the U.S., they’ve concentrated much of their research efforts to date in that arena. Previously, Cenegenics with von Schwarz submitted scientific review papers on erectile dysfunction as a complication of heart failure, growth hormone/testosterone in heart failure therapy and testosterone therapy as a treatment of metabolic disturbances in heart failure.

CERF also is forging research collaborations to investigate other avenues of the aging process—including nutraceuticals that may help slow the aging process and reduce some age-related occurrences, such as oxidative stress, telomere shortening and stem cell depletion.

For more information about Cenegenics, visit their site. Register for quick access to the informative Guide to Healthy Aging, Executive Summary and media excerpts. To schedule an interview, please contact Ann Castro, Cenegenics Director of Media Relations: 702.953.1588.

About Ernst R. von Schwarz, MD, PhD, FESC, FACC, FSCAI
Dr. Ernst R. von Schwarz is board certified in internal medicine by the American Board of Internal Medicine and in cardiology/cardiovascular diseases by the American Board of Internal Medicine. His primary clinical interests are end-stage heart failure, cardiac transplantation, interventional cardiology and sexual function in cardiac disease. He is a noted professor of medicine at UCLA’s David Geffen School of Medicine. As a clinician and scientist, Schwarz has written more than 100 articles for peer-reviewed publications and has written 10 book chapters on cardiovascular medicine.

About Cenegenics
Cenegenics® Medical Institute—the recognized leading authority in age management medicine —offers their highly regarded approach to optimal health at centers nationwide: Las Vegas, Nevada (Cenegenics Las Vegas and Cenegenics-Life Center); Charleston, South Carolina; Boca Raton, Florida; Dallas, Texas; Fort Worth, Texas; Atlanta, Georgia; Chicago, Illinois; Beverly Hills, California; Philadelphia, Pennsylvania; Washington, DC; New York City, New York; Tulsa, Oklahoma; Jacksonville, Florida. Additional centers are scheduled to open in other metropolitan areas in the near future. With an established presence in the medical community, Cenegenics uses a proactive approach based on solid science and comprehensive evaluation. Their established protocols have been recognized as the next generation of medical science, capturing global attention. Cenegenics offers CME-accredited physician training and certification opportunities in age management medicine via the nonprofit Cenegenics Education and Research Foundation (CERF). Headquartered in Las Vegas, Cenegenics serves more than 20,000 patients worldwide—2,000 are physicians and their families.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ann Castro, Director of Media Relations